Tiagabine for the Treatment of Cocaine Dependence - 1

To assess the efficacy and safety of tiagabine in reducing cocaine use in subjects with
cocaine dependence. It is hypothesized that tiagabine treatment, compared to placebo, will
be associated with fewer days of cocaine use as assessed by self-report confirmed with urine
assays for benzoylecgonine (BE). This is a double-blind, placebo-controlled, parallel-group
design study, in which, after screening and a 2-week baseline assessment period, subjects
will be equally randomly assigned to 1 of 2 treatment groups, tiagabine or matched placebo.

Inclusion Criteria:

Must be at least 18 years of age and be seeking treatment for cocaine dependence. Have the
ability to understand, and having understood, provide written informed consent. If female,
agree to use a method of birth control as indicated by the clinician. Please contact the
participating site in your area for more information.

Exclusion Criteria:

Please contact the participating site in your area for more information.